ID   PTEN_MOUSE              Reviewed;         403 AA.
AC   O08586; Q3UFB0; Q542G1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   18-JUN-2025, entry version 224.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000250|UniProtKB:P60484};
DE            EC=3.1.3.16 {ECO:0000250|UniProtKB:P60484};
DE            EC=3.1.3.48 {ECO:0000250|UniProtKB:P60484};
DE            EC=3.1.3.67 {ECO:0000250|UniProtKB:P60484};
DE   AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000250|UniProtKB:P60484};
DE            EC=3.1.3.- {ECO:0000250|UniProtKB:P60484};
DE   AltName: Full=Mutated in multiple advanced cancers 1;
DE   AltName: Full=Phosphatase and tensin homolog;
GN   Name=Pten; Synonyms=Mmac1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9090379; DOI=10.1038/ng0497-356;
RA   Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H.,
RA   Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R.,
RA   Swedlund B., Teng D.H.-F., Tavtigian S.V.;
RT   "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome
RT   10q23.3 that is mutated in multiple advanced cancers.";
RL   Nat. Genet. 15:356-363(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD;
RC   TISSUE=Sympathetic ganglion, Testis, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Czech II; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION.
RX   PubMed=10339565; DOI=10.1073/pnas.96.11.6199;
RA   Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N.,
RA   Mueller B., Liu X., Wu H.;
RT   "PTEN modulates cell cycle progression and cell survival by regulating
RT   phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B
RT   signaling pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6199-6204(1999).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-385, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [6]
RP   UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   XIAP/BIRC4.
RX   PubMed=19473982; DOI=10.1074/jbc.c109.009522;
RA   Van Themsche C., Leblanc V., Parent S., Asselin E.;
RT   "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN
RT   ubiquitination, content, and compartmentalization.";
RL   J. Biol. Chem. 284:20462-20466(2009).
RN   [7]
RP   FUNCTION.
RX   PubMed=19778506; DOI=10.1016/j.neuron.2009.08.008;
RA   Kim J.Y., Duan X., Liu C.Y., Jang M.H., Guo J.U., Pow-anpongkul N.,
RA   Kang E., Song H., Ming G.L.;
RT   "DISC1 regulates new neuron development in the adult brain via modulation
RT   of AKT-mTOR signaling through KIAA1212.";
RL   Neuron 63:761-773(2009).
RN   [8]
RP   PHOSPHORYLATION AT SER-380; THR-382 AND THR-383, AND INTERACTION WITH
RP   ROCK1.
RX   PubMed=20008297; DOI=10.1182/blood-2009-08-237222;
RA   Vemula S., Shi J., Hanneman P., Wei L., Kapur R.;
RT   "ROCK1 functions as a suppressor of inflammatory cell migration by
RT   regulating PTEN phosphorylation and stability.";
RL   Blood 115:1785-1796(2010).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 AND SER-385, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, and Lung;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   PHOSPHORYLATION AT THR-366 AND SER-370.
RX   PubMed=20940307; DOI=10.1074/jbc.m110.166462;
RA   Xu D., Yao Y., Jiang X., Lu L., Dai W.;
RT   "Regulation of PTEN stability and activity by Plk3.";
RL   J. Biol. Chem. 285:39935-39942(2010).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25801959; DOI=10.1093/jmcb/mjv020;
RA   Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J.,
RA   Silke J., Tan S.S.;
RT   "Ndfip1 represses cell proliferation by controlling Pten localization and
RT   signaling specificity.";
RL   J. Mol. Cell Biol. 7:119-131(2015).
RN   [12]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=31492966; DOI=10.1007/s00018-019-03280-5;
RA   Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.;
RT   "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by
RT   targeting PTEN degradation.";
RL   Cell. Mol. Life Sci. 77:2181-2197(2020).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, PHOSPHORYLATION,
RP   DOMAIN, AND MUTAGENESIS OF 399-GLN--VAL-403.
RX   PubMed=33428810; DOI=10.15252/emmm.202012632;
RA   Bae M., Roh J.D., Kim Y., Kim S.S., Han H.M., Yang E., Kang H., Lee S.,
RA   Kim J.Y., Kang R., Jung H., Yoo T., Kim H., Kim D., Oh H., Han S., Kim D.,
RA   Han J., Bae Y.C., Kim H., Ahn S., Chan A.M., Lee D., Kim J.W., Kim E.;
RT   "SLC6A20 transporter: a novel regulator of brain glycine homeostasis and
RT   NMDAR function.";
RL   EMBO Mol. Med. 13:e12632-e12632(2021).
CC   -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating
CC       tyrosine-, serine- and threonine-phosphorylated proteins. Also
CC       functions as a lipid phosphatase, removing the phosphate in the D3
CC       position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol
CC       3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate
CC       and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for
CC       PtdIns(3,4,5)P3. Furthermore, this enzyme can also act as a cytosolic
CC       inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6
CC       pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5-
CC       tetrakisphosphate (By similarity). Antagonizes the PI3K-AKT/PKB
CC       signaling pathway by dephosphorylating phosphoinositides and thereby
CC       modulating cell cycle progression and cell survival (PubMed:10339565,
CC       PubMed:19778506, PubMed:31492966). The unphosphorylated form cooperates
CC       with MAGI2 to suppress AKT1 activation. In motile cells, suppresses the
CC       formation of lateral pseudopods and thereby promotes cell polarization
CC       and directed movement. Dephosphorylates tyrosine-phosphorylated focal
CC       adhesion kinase and inhibits cell migration and integrin-mediated cell
CC       spreading and focal adhesion formation (By similarity). Required for
CC       growth factor-induced epithelial cell migration; growth factor
CC       stimulation induces PTEN phosphorylation which changes its binding
CC       preference from the p85 regulatory subunit of the PI3K kinase complex
CC       to DLC1 and results in translocation of the PTEN-DLC1 complex to the
CC       posterior of migrating cells to promote RHOA activation (By
CC       similarity). Meanwhile, TNS3 switches binding preference from DLC1 to
CC       p85 and the TNS3-p85 complex translocates to the leading edge of
CC       migrating cells to activate RAC1 activation (By similarity). Plays a
CC       role as a key modulator of the AKT-mTOR signaling pathway controlling
CC       the tempo of the process of newborn neurons integration during adult
CC       neurogenesis, including correct neuron positioning, dendritic
CC       development and synapse formation (PubMed:10339565, PubMed:19778506).
CC       Involved in the regulation of synaptic function in excitatory
CC       hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA
CC       receptor activation, is required for the modulation of synaptic
CC       activity during plasticity. Enhancement of lipid phosphatase activity
CC       is able to drive depression of AMPA receptor-mediated synaptic
CC       responses, activity required for NMDA receptor-dependent long-term
CC       depression (LTD) (By similarity). May be a negative regulator of
CC       insulin signaling and glucose metabolism in adipose tissue. The nuclear
CC       monoubiquitinated form possesses greater apoptotic potential, whereas
CC       the cytoplasmic nonubiquitinated form induces less tumor suppressive
CC       ability (By similarity). {ECO:0000250|UniProtKB:O54857,
CC       ECO:0000250|UniProtKB:P60484, ECO:0000269|PubMed:10339565,
CC       ECO:0000269|PubMed:19778506, ECO:0000269|PubMed:31492966}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456; EC=3.1.3.67;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978; EC=3.1.3.48;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416,
CC         ChEBI:CHEBI:83419; Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-
CC         3-phospho-(1D-myo-inositol-4,5-bisphosphate) + phosphate;
CC         Xref=Rhea:RHEA:43560, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83420, ChEBI:CHEBI:83423;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo-
CC         inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627,
CC         ChEBI:CHEBI:57733; Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo-
CC         inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895,
CC         ChEBI:CHEBI:203600; Evidence={ECO:0000250|UniProtKB:P60484};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156;
CC         Evidence={ECO:0000250|UniProtKB:P60484};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second
CC       PDZ domain of MAGI2 (By similarity). Interacts with MAGI2, MAGI3, MAST1
CC       and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2
CC       increases protein stability (By similarity). Interacts with NEDD4 (By
CC       similarity). Interacts with NDFIP1 and NDFIP2; in the presence of NEDD4
CC       or ITCH, this interaction promotes PTEN ubiquitination (By similarity).
CC       Interacts (via C2 domain) with FRK (By similarity). Interacts with
CC       USP7; the interaction is direct (By similarity). Interacts with ROCK1
CC       (PubMed:20008297). Interacts with XIAP/BIRC4 (PubMed:19473982).
CC       Interacts with STK11; the interaction phosphorylates PTEN (By
CC       similarity). Interacts with PPP1R16B (By similarity). Interacts with
CC       NOP53; regulates PTEN phosphorylation and increases its stability (By
CC       similarity). Interacts (via PDZ domain-binding motif) with DLG4; the
CC       interaction is induced by NMDA and is required for PTEN location at
CC       postsynaptic density (By similarity). Interacts with the regulatory p85
CC       subunit of the PI3K kinase complex and with Rho GTPase-activating
CC       protein DLC1; in resting cells, interacts (via C2 tensin-type domain)
CC       with p85 but, following growth factor stimulation, PTEN is
CC       phosphorylated which leads to weakened interaction with p85 and
CC       enhanced interaction (via C2 tensin-type domain) with DLC1 while p85
CC       interaction with TNS3 increases (By similarity).
CC       {ECO:0000250|UniProtKB:O54857, ECO:0000250|UniProtKB:P60484,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:20008297}.
CC   -!- INTERACTION:
CC       O08586; P49452: Cenpc; NbExp=2; IntAct=EBI-1186266, EBI-1186252;
CC       O08586; Q9JHL1: Nherf2; NbExp=3; IntAct=EBI-1186266, EBI-538451;
CC       O08586; B1AZ99: Otud3; NbExp=2; IntAct=EBI-1186266, EBI-16170692;
CC       O08586; P02340: Tp53; NbExp=4; IntAct=EBI-1186266, EBI-474016;
CC       O08586; P62991: Ubc; NbExp=2; IntAct=EBI-1186266, EBI-413074;
CC       O08586; Q6A4J8: Usp7; NbExp=2; IntAct=EBI-1186266, EBI-1216254;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:25801959}. Nucleus {ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:25801959}. Nucleus, PML body
CC       {ECO:0000250|UniProtKB:P60484}. Cell projection, dendritic spine
CC       {ECO:0000269|PubMed:33428810}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear
CC       (By similarity). Nonubiquitinated form is cytoplasmic (By similarity).
CC       Colocalized with PML and USP7 in PML nuclear bodies (By similarity).
CC       XIAP/BIRC4 promotes its nuclear localization (PubMed:19473982).
CC       Associares with the postsynaptic density in response to NMDAR
CC       activation (By similarity). {ECO:0000250|UniProtKB:O54857,
CC       ECO:0000250|UniProtKB:P60484, ECO:0000269|PubMed:19473982}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain (at protein level).
CC       {ECO:0000269|PubMed:33428810}.
CC   -!- PTM: Constitutively phosphorylated by CK2 under normal conditions.
CC       Phosphorylation results in an inhibited activity towards PIP3.
CC       Phosphorylation can both inhibit or promote PDZ-binding.
CC       Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from
CC       ubiquitin-mediated degradation probably by inhibiting its binding to
CC       NEDD4 (By similarity). Phosphorylation by PLK3 promotes its stability
CC       and prevents its degradation by the proteasome. Phosphorylation by
CC       ROCK1 is essential for its stability and activity. Phosphorylated on
CC       Thr-319 and Thr-321 in the C2-type tensin domain following EGF
CC       stimulation which changes its binding preference from the p85
CC       regulatory subunit of the PI3K kinase complex to DLC1 (By similarity).
CC       {ECO:0000250|UniProtKB:P60484, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:20008297, ECO:0000269|PubMed:20940307}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of
CC       retinoic acid. Deubiquitinated by USP7; leading to its nuclear
CC       exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino
CC       acid is sufficient to modulate PTEN compartmentalization (By
CC       similarity). Ubiquitinated by XIAP/BIRC4. {ECO:0000250,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex,
CC       leading to its degradation. {ECO:0000269|PubMed:31492966}.
CC   -!- PTM: ISGylated. ISGylation promotes PTEN degradation.
CC       {ECO:0000250|UniProtKB:P60484}.
CC   -!- SIMILARITY: Belongs to the PTEN phosphatase protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U92437; AAC53118.1; -; mRNA.
DR   EMBL; AK076980; BAC36545.1; -; mRNA.
DR   EMBL; AK088717; BAC40525.1; -; mRNA.
DR   EMBL; AK148736; BAE28651.1; -; mRNA.
DR   EMBL; BC021445; AAH21445.1; -; mRNA.
DR   CCDS; CCDS29753.1; -.
DR   RefSeq; NP_032986.1; NM_008960.2.
DR   AlphaFoldDB; O08586; -.
DR   SMR; O08586; -.
DR   BioGRID; 202449; 291.
DR   ComplexPortal; CPX-3154; PTEN phosphatase complex.
DR   DIP; DIP-38740N; -.
DR   FunCoup; O08586; 4176.
DR   IntAct; O08586; 24.
DR   MINT; O08586; -.
DR   STRING; 10090.ENSMUSP00000013807; -.
DR   iPTMnet; O08586; -.
DR   PhosphoSitePlus; O08586; -.
DR   jPOST; O08586; -.
DR   PaxDb; 10090-ENSMUSP00000013807; -.
DR   PeptideAtlas; O08586; -.
DR   ProteomicsDB; 302005; -.
DR   Pumba; O08586; -.
DR   Antibodypedia; 3420; 1732 antibodies from 53 providers.
DR   DNASU; 19211; -.
DR   Ensembl; ENSMUST00000013807.8; ENSMUSP00000013807.8; ENSMUSG00000013663.9.
DR   GeneID; 19211; -.
DR   KEGG; mmu:19211; -.
DR   UCSC; uc008hfr.1; mouse.
DR   AGR; MGI:109583; -.
DR   CTD; 5728; -.
DR   MGI; MGI:109583; Pten.
DR   VEuPathDB; HostDB:ENSMUSG00000013663; -.
DR   eggNOG; KOG2283; Eukaryota.
DR   GeneTree; ENSGT00940000163053; -.
DR   HOGENOM; CLU_020105_5_2_1; -.
DR   InParanoid; O08586; -.
DR   OMA; CKKFKQR; -.
DR   OrthoDB; 16692at2759; -.
DR   PhylomeDB; O08586; -.
DR   Reactome; R-MMU-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-MMU-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-MMU-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-MMU-202424; Downstream TCR signaling.
DR   Reactome; R-MMU-5689880; Ub-specific processing proteases.
DR   Reactome; R-MMU-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-MMU-8948747; Regulation of PTEN localization.
DR   Reactome; R-MMU-8948751; Regulation of PTEN stability and activity.
DR   BioGRID-ORCS; 19211; 22 hits in 89 CRISPR screens.
DR   ChiTaRS; Pten; mouse.
DR   PRO; PR:O08586; -.
DR   Proteomes; UP000000589; Chromosome 19.
DR   RNAct; O08586; protein.
DR   Bgee; ENSMUSG00000013663; Expressed in retrosplenial region and 283 other cell types or tissues.
DR   ExpressionAtlas; O08586; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; IDA:BHF-UCL.
DR   GO; GO:0043005; C:neuron projection; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IDA:BHF-UCL.
DR   GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; ISS:UniProtKB.
DR   GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:MGI.
DR   GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; ISS:UniProtKB.
DR   GO; GO:1990757; F:ubiquitin ligase activator activity; IMP:BHF-UCL.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; ISO:MGI.
DR   GO; GO:0030534; P:adult behavior; IMP:CACAO.
DR   GO; GO:0001525; P:angiogenesis; IMP:MGI.
DR   GO; GO:0006915; P:apoptotic process; IGI:MGI.
DR   GO; GO:0042100; P:B cell proliferation; IMP:MGI.
DR   GO; GO:0048854; P:brain morphogenesis; IMP:CACAO.
DR   GO; GO:0048738; P:cardiac muscle tissue development; IMP:MGI.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0008283; P:cell population proliferation; IMP:MGI.
DR   GO; GO:0036294; P:cellular response to decreased oxygen levels; IDA:MGI.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:MGI.
DR   GO; GO:0007417; P:central nervous system development; IMP:MGI.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; IMP:BHF-UCL.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; IMP:CACAO.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0021542; P:dentate gyrus development; IMP:CACAO.
DR   GO; GO:0043542; P:endothelial cell migration; IMP:MGI.
DR   GO; GO:0048853; P:forebrain morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0010467; P:gene expression; IGI:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0007611; P:learning or memory; IMP:CACAO.
DR   GO; GO:0045475; P:locomotor rhythm; IMP:CACAO.
DR   GO; GO:0007626; P:locomotory behavior; IMP:CACAO.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IMP:BHF-UCL.
DR   GO; GO:0060179; P:male mating behavior; IMP:CACAO.
DR   GO; GO:0042711; P:maternal behavior; IMP:CACAO.
DR   GO; GO:0033555; P:multicellular organismal response to stress; IMP:BHF-UCL.
DR   GO; GO:0042552; P:myelination; IMP:MGI.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0048681; P:negative regulation of axon regeneration; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; IMP:BHF-UCL.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:MGI.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IGI:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IGI:MGI.
DR   GO; GO:0045792; P:negative regulation of cell size; IMP:CACAO.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0061002; P:negative regulation of dendritic spine morphogenesis; IMP:CACAO.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:MGI.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; IMP:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0031642; P:negative regulation of myelination; IMP:MGI.
DR   GO; GO:0046621; P:negative regulation of organ growth; IMP:CACAO.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB.
DR   GO; GO:0090071; P:negative regulation of ribosome biogenesis; IMP:CACAO.
DR   GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; IMP:CACAO.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IMP:MGI.
DR   GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:MGI.
DR   GO; GO:0007270; P:neuron-neuron synaptic transmission; IMP:BHF-UCL.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:MGI.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IEA:InterPro.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:MGI.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IMP:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; IMP:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; IMP:CACAO.
DR   GO; GO:0097105; P:presynaptic membrane assembly; IMP:BHF-UCL.
DR   GO; GO:0060736; P:prostate gland growth; IMP:MGI.
DR   GO; GO:0006470; P:protein dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0048679; P:regulation of axon regeneration; IGI:MGI.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; IMP:MGI.
DR   GO; GO:0051726; P:regulation of cell cycle; IGI:MGI.
DR   GO; GO:0032535; P:regulation of cellular component size; IMP:CACAO.
DR   GO; GO:0060341; P:regulation of cellular localization; IMP:CACAO.
DR   GO; GO:2000109; P:regulation of macrophage apoptotic process; IMP:MGI.
DR   GO; GO:0010975; P:regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; ISS:UniProtKB.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IMP:MGI.
DR   GO; GO:0060024; P:rhythmic synaptic transmission; IMP:CACAO.
DR   GO; GO:0035176; P:social behavior; IMP:CACAO.
DR   GO; GO:0007416; P:synapse assembly; IMP:BHF-UCL.
DR   GO; GO:0060074; P:synapse maturation; IMP:BHF-UCL.
DR   GO; GO:0042098; P:T cell proliferation; IMP:MGI.
DR   CDD; cd14509; PTP_PTEN; 1.
DR   FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1.
DR   FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1.
DR   Gene3D; 2.60.40.1110; -; 1.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1.
DR   InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR051281; Dual-spec_lipid-protein_phosph.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR045101; PTP_PTEN.
DR   InterPro; IPR014020; Tensin_C2-dom.
DR   InterPro; IPR029023; Tensin_phosphatase.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1.
DR   PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1.
DR   Pfam; PF10409; PTEN_C2; 1.
DR   Pfam; PF22785; Tc-R-P; 1.
DR   PIRSF; PIRSF038025; PTEN; 1.
DR   SMART; SM01326; PTEN_C2; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SMART; SM01301; PTPlike_phytase; 1.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   PROSITE; PS51182; C2_TENSIN; 1.
DR   PROSITE; PS51181; PPASE_TENSIN; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   TreeFam; TF324513; -.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; Cell projection; Cytoplasm; Hydrolase;
KW   Isopeptide bond; Lipid metabolism; Neurogenesis; Nucleus; Phosphoprotein;
KW   Protein phosphatase; Reference proteome; Synapse; Tumor suppressor;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   CHAIN           2..403
FT                   /note="Phosphatidylinositol 3,4,5-trisphosphate 3-
FT                   phosphatase and dual-specificity protein phosphatase PTEN"
FT                   /id="PRO_0000215905"
FT   DOMAIN          14..185
FT                   /note="Phosphatase tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   DOMAIN          190..350
FT                   /note="C2 tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00589"
FT   REGION          338..348
FT                   /note="Required for interaction with NOP53"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   REGION          352..403
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           401..403
FT                   /note="PDZ domain-binding"
FT                   /evidence="ECO:0000305|PubMed:33428810"
FT   COMPBIAS        360..369
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        383..393
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        124
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   MOD_RES         2
FT                   /note="N-acetylthreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         319
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   MOD_RES         321
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   MOD_RES         336
FT                   /note="Phosphotyrosine; by FRK"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   MOD_RES         366
FT                   /note="Phosphothreonine; by GSK3-beta and PLK3"
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MOD_RES         370
FT                   /note="Phosphoserine; by CK2 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MOD_RES         380
FT                   /note="Phosphoserine; by ROCK1"
FT                   /evidence="ECO:0000269|PubMed:20008297,
FT                   ECO:0000269|PubMed:33428810"
FT   MOD_RES         382
FT                   /note="Phosphothreonine; by ROCK1"
FT                   /evidence="ECO:0000269|PubMed:20008297,
FT                   ECO:0000269|PubMed:33428810"
FT   MOD_RES         383
FT                   /note="Phosphothreonine; by ROCK1"
FT                   /evidence="ECO:0000269|PubMed:20008297,
FT                   ECO:0000269|PubMed:33428810"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         401
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   CROSSLNK        13
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   CROSSLNK        289
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P60484"
FT   MUTAGEN         399..403
FT                   /note="Missing: Reduced excitatory synapse density in
FT                   hippocampus. Decreased NMDAR-mediated synaptic
FT                   transmission. Increased brain glycine levels."
FT                   /evidence="ECO:0000269|PubMed:33428810"
FT   CONFLICT        50
FT                   /note="Missing (in Ref. 2; BAE28651)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   403 AA;  47152 MW;  75F97C3DD6843BA9 CRC64;
     MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK
     HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA
     AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY
     LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY
     FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI
     DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS
     SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHSQI TKV
//
